Obermatt
See Similar Stocks →

Cassava Sciences

NAQ:SAVA · US14817C1071
PharmaceuticalsSmall

360

20
Medium confidence — indicative
EV / EBIT93
Price / Owner Earnings55
Owner Earnings Yield1
Dividend Yield1
Sales & asset price31
Return on Capital22
Cash Return on Capital4
Return on Equity10
Profit margins1

Cash truth not applicable for financial companies.

Sales growth—
Profit growth27
Reinvestment72
Price momentum18
Debt load96
Refinancing1
Debt Payback1
Liquidity55
Analyst ratings43
Expectations trend99
Market mood4
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Cassava Sciences doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 4/5 components.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded1998
Employees16
Websitecassavasciences.com
ISINUS14817C1071
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsChronic DiseasesNeurologyCentral Nervous SystemNeuroscienceBiotechnologyHealth CareScience and Engineering

Description

Filana Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company’s science is based on modulating the activity of a critical protein in the brain for patients with certain central nervous system (CNS) disorders, such as TSC.…

Analysis

Weak and unloved

Filana Therapeutics, Inc. scores below average on quality and is priced accordingly, a low-conviction position in either direction.

Valuation data is not available for this company.

Growth is mixed; the safety picture is stretched. The company scores 2/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

Similar Stocks

The companies this stock is ranked against.

Compare Cassava Sciences with its peers
Edgewise Therapeutics
NSQ:EWTX
49
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Cognition Therapeutics
NAQ:CGTX
—
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Aardvark Therapeutics
NSQ:AARD
29
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
LB Pharmaceuticals
NMQ:LBRX
79
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Ventyx Biosciences
NSQ:VTYX
51
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Contineum Therapeutics
NSQ:CTNM
80
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →